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Introduction: Although lung cancer is the leading cause of cancer 
death in women, few studies have investigated the hormonal influ-
ence on survival after a lung cancer diagnosis and results have been 
inconsistent. We evaluated the role of reproductive and hormonal 
factors in predicting overall survival in women with non–small-cell 
lung cancer (NSCLC).
Methods: Population-based lung cancer cases diagnosed between 
November 1, 2001 and October 31, 2005 were identified through 
the Metropolitan Detroit Surveillance, Epidemiology, and End 
Results Registry. Interview and follow-up data were collected for 
485 women. Cox proportional hazard regression models were used 
to determine hazard ratios (HRs) for death after an NSCLC diagnosis 
associated with reproductive and hormonal variables.
Results: Use of hormone therapy (HT) was associated with improved 
survival (HR, 0.69; 95% confidence interval, 0.54–0.89), adjusting 
for stage, surgery, radiation, education level, pack-years of smoking, 
age at diagnosis, race, and a multiplicative interaction between stage 
and radiation. No other reproductive or hormonal factor was asso-
ciated with survival after an NSCLC diagnosis. Increased duration 
of HT use before the lung cancer diagnosis (132 months or longer) 
was associated with improved survival (HR, 0.54; 95% confidence 
interval, 0.37–0.78), and this finding remained significant in women 
taking either estrogen alone or progesterone plus estrogen, never 
smokers, and smokers.
Conclusion: These findings suggest that HT use, in particular use 
of estrogen plus progesterone, and long-term HT use are associated 
with improved survival of NSCLC.
Key Words: Non–small-cell lung cancer, Hormone use, Survival.
(J Thorac Oncol. 2014;9: 355–361)
In the United States, lung cancer is the leading cause of can-cer death in both men and women. It is estimated that in 
2012, 116,470 men and 109,690 women were diagnosed with 
lung cancer and 87,750 men and 72,590 women died from the 
disease.1 Since 1990, lung cancer mortality in men has been 
decreasing, whereas in women mortality has only seen a slight 
decrease since 2004.2
Many studies have explored sex differences in lung 
cancer incidence. Although differences in smoking patterns 
in men and women contribute to the variations in lung can-
cer risk, these differences do not fully explain incidence rate 
variation.3 That women are more likely to develop adenocar-
cinomas and develop cancer at a younger age suggests alter-
native biological explanations.4 Reproductive and hormonal 
factors contributing to the risk of lung cancer have been stud-
ied, particularly the role of estrogens in cancer development, 
with inconsistent results.5–13
Sex differences also exist in survival; female lung can-
cer patients have better survival compared with the survival 
in male lung cancer patients.14–16 The influence of reproduc-
tive factors on lung cancer survival has not been extensively 
studied. Moore et al. investigated the influence of menopausal 
status on outcomes of lung cancer and found that even though 
premenopausal women had tumors of an advanced clinical 
stage, overall survival was not significantly different from 
survival of postmenopausal women. The authors suggest that 
lifelong exposure to estrogen may offer a protective effect in 
lung cancer progression.17
Research on hormone therapy (HT) use and outcomes 
from lung cancer is limited, and results have been mixed. In a 
retrospective study, Ganti et al.18 found that women taking HT 
had decreased survival compared with women who had never 
used HT. The Women’s Health Initiative (WHI) randomized 
control trial study showed that the use of estrogen-only HT 
was not associated with incidence or mortality from lung can-
cer.8 In the WHI study, combined estrogen and progesterone 
HT use was associated with an increased mortality, but not 
associated with incidence of lung cancer among postmeno-
pausal women.9 Two other studies did not reveal an associa-
tion between HT use and lung cancer outcomes.19,20
The purpose of our study was to investigate whether repro-
ductive factors are associated with overall survival in female 
non–small-cell lung cancer (NSCLC) patients and to further 
explore the role of HT use on survival of women with NSCLC.
MATERIALS AND METHODS
Study Participants
Lung cancer cases diagnosed between November 1, 
2001 and October 31, 2005 were identified through the 
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population-based Metropolitan Detroit Cancer Surveillance 
System, a member of the National Cancer Institute’s 
Surveillance, Epidemiology, and End Results program. 
Women aged 18 to 74, diagnosed with NSCLC, and residing 
in Wayne, Macomb, and Oakland were eligible to participate. 
Eligibility criteria were originally restricted to adenocarci-
noma cases, but were extended after November 1, 2004 to 
include all other types of NSCLC as many histologic diagno-
ses were not more specific.
Detailed in-person interviews were completed for 577 
women (60%); 273 women refused participation and 129 
reported being too ill to participate. Participation rates were 
58% in white and 63% in African American women. Cases with 
reported race other than African American or white (n = 13), 
women with unknown menstrual status or those whose men-
ses were possibly affected by previous lung cancer treatment 
(n = 20), and women with a previous breast cancer diagnosis 
(n = 59) were excluded. After applying these exclusion criteria, 
485 women with NSCLC were included in our analysis.
Data Collection
The study was approved by the institutional review board 
and all participants signed a written informed consent. Surveys 
collected demographic information, medical history, smoking 
history, reproductive history, and environmental tobacco expo-
sure. Reproductive history included age at first birth, age of 
menarche, age of menopause, oral contraceptive use and dura-
tion before lung cancer diagnosis, and hormone use and duration 
before lung cancer diagnosis. Details of HT type (estrogen only, 
estrogen and progesterone combined, and progesterone only) 
and dose were collected. Data collected on a number of risk fac-
tors for NSCLC have been published previously.21–24 NSCLC 
diagnoses dates, histology, and treatment data were collected 
through the Metropolitan Detroit Cancer Surveillance System.
Statistical Analysis
Statistical analyses were carried out using SAS version 
9.2 (SAS Institute, Cary, NC). Student’s t tests were used to 
compare means of continuous variables, whereas compari-
sons of categorical variables were performed using χ2 tests. 
A Wilcoxon rank-sum test was used to compare medians 
between groups. All demographic, treatment, reproductive, 
and hormonal variables were first included in a univariate Cox 
proportional hazards regression model to assess the influence 
of the variable on survival. Nonhormonal and nonreproductive 
factors such as stage, treatment with surgery, treatment with 
radiation, income, age at diagnosis, pack-years, and race were 
included in all models. Stepwise regression methods were 
used to identify reproductive and hormonal variables associ-
ated with outcome. Reproductive and hormonal factors that 
met significance at the p value less than 0.05 level remained in 
the model. Additional models included HT duration (catego-
rized: 0 months, 1–41 months, 42–131 months, 132 months, 
or longer before lung cancer diagnosis). HT duration was 
selected as the measure of exposure for additional analyses 
because dose data were missing for 41% of women reporting 
progesterone use and 45% of women reporting estrogen use. 
Of those women reporting doses, the majority reported using 
doses of 2.5 mg of progesterone and 0.625 mg of estrogen. 
With little variation in reported dose, duration of use was used 
to evaluate cumulative exposure. Models stratifying on meno-
pausal status, HT type, and smoking status were also devel-
oped. No interaction between ever smoking and hormone use 
was found in any of the models. A level of 0.05 was used to 
assess the statistical significance of p values in all analyses.
RESULTS
Subject characteristics are listed in Table 1. Of the 485 
women, 76.9% of the cases were white, and most were current 
or former smokers (92.3%); 91.6% of the women were post-
menopausal and 72.0% had used oral contraceptives; 72.8% of 
the cases presented with an adenocarcinoma histology. Stage 
of diagnosis was balanced with about  one-third of the women 
diagnosed in each of the local, regional, and distant stages.
Of the 485 women, 230 women (47.4%) had taken 
HT. Women who had taken HT were more likely to be white 
(p < 0.001), to have quit smoking (p = 0.03), had a higher 
education level (p < 0.001), and were at a higher income 
level (p = 0.02) compared with those who had never taken 
HT. HT type was determined for 187 women of the 230 who 
used hormones. Of those who used hormones, 99 women had 
taken estrogen only, three had taken progesterone only, and 85 
had taken the combined estrogen and progesterone formula-
tion. The women taking the combined therapy were older at 
menopause (mean years 46 versus 41.4; p < 0.001), but there 
were no other significant differences between the users of each 
hormone formulation in race, smoking status, pack-years, HT 
duration, or education level.
After adjusting for stage at diagnosis, surgery, radiation, 
education level, pack-years, age, race, and a multiplicative 
interaction between stage and radiation, the only reproductive 
or hormonal factor that predicted survival after NSCLC diag-
nosis was hormone use (hazard ratio [HR], 0.69; 95% confi-
dence interval [CI], 0.54–0.89) (Table 2). Although HRs were 
reduced for all duration of use categories, hormone use of 132 
months (11 years) or more before lung cancer diagnosis was 
significantly associated with better survival (HR, 0.54; 95% 
CI, 0.37–0.78). Age at first birth, age of first menstrual period, 
age of last menstrual period, number of pregnancies, number 
of children, oral contraceptive use and duration, infertility, or 
average length of days between menstrual cycles did not pre-
dict survival.
Ever use of HT did not significantly predict survival 
for women who took estrogen-only HT (HR, 0.79; 95% CI, 
0.59–1.04), unless use of estrogen was for 11 years or lon-
ger in which case survival was improved (HR, 0.58; 95% CI, 
0.37–0.92). Hormone use for those taking combined estrogen 
and progesterone was associated with significantly improved 
survival (HR, 0.64; 95% CI, 0.47–0.86). Although HRs were 
reduced for all duration of use categories, duration of HT was 
only statistically significantly associated with survival among 
those with 11 years or more of combined estrogen and proges-
terone use (HR, 0.50; 95% CI, 0.30–0.83) (Fig. 1).
The significance of hormone use did not change when 
restricting our analyses to postmenopausal women (n = 444). 
As in our analysis of all women, duration of more than 11 
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years of HT use was significant in this subgroup analysis. 
Hormone use was also predictive of survival in both never 
smokers and in ever smokers, and duration of HT use of 11 
years was significantly protective in both groups.
Lung cancer was the recorded cause of death for 84.5% 
of the cases who died. Ever use of hormones remained signifi-
cant when restricting the analyses to women with a lung can-
cer–specific cause of death (HR, 0.69; 95% CI, 0.53–0.90). 
TABLE 1.  Subject Characteristics and Hormone Therapy Status
Variable
All Women
N = 485
n (%)a
Hormone Therapyb
p
Type of Hormone Therapy
p
Yes
N = 230
n (%)a
No
N = 254
n (%)a
Estrogen Only
N = 99
n (%)a
Combined Estrogen + Progesterone
N = 85
n (%)a
Median survival time, mo 50.0 80.0 37.5 <0.001 83.0 87.0 0.83
Age, mean ± SD 60.1 ± 9.0 61.8 ± 7.6 58.6 ± 9.8 <0.001 62.3 ± 7.2 59.6 ± 7.4 0.01
Race <0.001 0.33
  White 373 (76.9) 198 (86.0) 174 (68.5) 81 (81.8) 74 (87.1)
  African American 112 (23.1) 32 (13.9) 80 (31.5) 18 (18.2) 11 (12.9)
Smoking statusc 0.03 0.06
  Never 37 (7.6) 17 (7.4) 20 (7.9) 12 (12.1) 3 (3.5)
  Ex-smoker 155 (32.0) 87 (37.8) 68 (26.9) 42 (42.4) 33 (38.8)
  Current 292 (60.3) 126 (54.8) 165 (65.2) 45 (45.5) 49 (57.7)
Histology 0.13 0.23
  Squamous cell 42 (8.7) 19 (8.3) 23 (9.1) 4 (4.0) 10 (11.8)
  Adenocarcinoma 353 (72.8) 178 (77.4) 174 (68.5) 80 (80.8) 61 (71.8)
  Large cell 13 (2.7) 5 (2.2) 8 (3.2) 3 (3.0) 2 (2.4)
  NSCLC, NOS 77 (15.9) 28 (12.2) 49 (19.29) 12 (12.1) 12 (14.1)
Pack-years of smokingd, mean ± SD 47.5 ± 29.5 49.3 ± 28.3 45.8 ± 30.5 0.22 49.2 ± 27.8 47.1 ± 27.9 0.62
Stage at diagnosise 0.01 0.47
  Local 162 (33.6) 88 (38.4) 74 (29.4) 42 (42.4) 30 (35.3)
  Regional 161 (33.4) 81 (35.4) 79 (31.4) 37 (37.4) 32 (37.7)
  Distant 159 (33.0) 60 (26.2) 99 (39.3) 20 (20.2) 23 (27.1)
Hormone therapy duration, mof 0.78
  1–41 73 (33.3) N/A N/A 31 (31.6) 21 (26.9)
  42–131 72 (32.8) 34 (34.7) 28 (35.9)
  132 74 (33.8) 33 (33.7) 29 (37.2)
Age at menopause, mean ± SD 44.2 ± 8.1 43.6 ± 8.1 44.7 ± 8.2 0.15 41.4 ± 7.6 46.0 ± 7.9 <0.001
Education levelg <0.001 0.62
  <High school 20 (4.1) 3 (1.3) 17 (6.7) 1 (1.0) 1 (1.2)
  High school 266 (55.0) 116 (50.7) 149 (58.7) 52 (52.5) 38 (45.2)
  >High school 198 (40.9) 110 (48.0) 88 (34.7) 46 (46.5) 45 (53.6)
Treatment with surgeryh <0.001 0.06
  No 195 (40.3) 74 (32.3) 120 (47.2) 25 (25.3) 32 (38.1)
  Yes 289 (59.7) 155 (67.7) 134 (52.8) 74 (74.8) 52 (61.9)
Treatment with radiationi 0.15 0.23
  No 278 (58.2) 140 (61.7) 138 (55.2) 61 (62.9) 46 (54.1)
  Yes 200 (41.8) 87 (38.3) 112 (44.8) 36 (37.1) 39 (45.9)
Vital status <0.01 0.58
  Alive 175 (36.1) 106 (46.1) 69 (27.2) 46 (46.5) 43 (50.6)
  Dead 310 (63.9) 124 (53.9) 185 (72.8) 53 (53.5) 42 (49.4)
aPercentages may not add to 100.0 because of rounding.
bHormone use was missing for one case.
cSmoking status was missing for one case.
dPack-years were missing for two cases.
eStage was missing for three cases.
fDuration of use was missing for 11 cases.
gEducation level was missing for one case.
hSurgery information was missing for one case.
iRadiation information was missing for seven cases.
NSCLC, non–small-cell lung cancer; NOS, not otherwise specified; N/A, not applicable.
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Ever use of hormones was also significantly associated with 
survival when the analysis was restricted to women with ade-
nocarcinoma of the lung (HR, 0.65; 95% CI, 0.49–0.87).
DISCUSSION
In this retrospective study, several reproductive factors 
were tested for their influence on survival after an NSCLC 
diagnosis. Age at first birth, number of children born, num-
ber of pregnancies, oral contraceptive use and duration, age 
of first or last menstrual period, infertility, and average length 
of days between menstrual cycles did not predict survival of 
NSCLC. However, increased duration of HT use was associ-
ated with a decreased risk of death after an NSCLC diagnosis. 
These findings suggest a complex relationship between expo-
sure to exogenous hormones and lung cancer outcomes.
Research examining the relationship between reproduc-
tive factors and lung cancer survival in women has been limited. 
Skuladottir and Olsen25 examined whether reproductive pat-
terns could predict outcomes of lung cancer in both men and 
women. They observed that women without children had worse 
prognoses than did parous women. The authors found a similar 
result in men without children, and concluded that the finding 
was not the result of hormones, but likely the result of lifestyle 
factors such as socioeconomic status. A more recent cohort study 
explored the impact of parity on the risk of death from lung can-
cer in Taiwan. With increasing parity, there was an increased risk 
of death although this trend was not significant (p = 0.25).26 That 
study was limited to premenopausal women, whereas our study 
is composed mainly of postmenopausal women. We did not find 
a significant association between parity and increased risk of 
death. Plasma estrogen levels are increased during pregnancy,27 
but the precise role of estrogens in lung cancer development and 
progression is still not fully understood.28 To our knowledge, to 
date, there have been no other findings on reproductive factors 
and effect on survival outcomes for lung cancer.
Observational studies on HT use and lung cancer out-
comes have been few and have resulted in conflicting find-
ings. Table 3 summarizes the literature in this area. Our study 
supports the findings of an observational study that reported 
reduced lung cancer mortality among long-term hormone 
TABLE 2.  Survival of NSCLC by HT Use and Duration of Use
All Women
HRa (95% CI)
Postmenopausal 
Women
HRa (95% CI)
Estrogen-Only HT 
Users
HRa (95% CI)
Estrogen + Progesterone 
HT Users
HRa (95% CI)
Never Smokers
HRa (95% CI)
Former and Current 
Smokers
HRa (95% CI)
Ever HT use 0.69 (0.54–0.88) 0.72 (0.56–0.92) 0.79 (0.59–1.04) 0.64 (0.47–0.86) 0.19 (0.05–0.73) 0.73 (0.57–0.94)
Duration of HT use, mo
  0–41 0.82 (0.57–1.17) 0.87 (0.60–1.25) 0.79 (0.52–1.21) 0.80 (0.51–1.26) 0.20 (0.02–1.75) 0.87 (0.60–1.25)
  42–131 0.81 (0.57–1.15) 0.83 (0.58–1.19) 0.98 (0.64–1.48) 0.70 (0.43–1.14) 0.78 (0.08–7.71) 0.83 (0.58–1.19)
  ≥132 0.54 (0.37–0.78) 0.56 (0.38–0.82) 0.58 (0.37–0.92) 0.50 (0.30–0.83) 0.12 (0.02–0.72) 0.75 (0.60–0.94)
aAdjusted for age at diagnosis, race, pack-years (continuous), education, stage at diagnosis, treatment with surgery, treatment with radiation, and the multiplicative interaction 
between stage and radiation.
NSCLC, non–small-cell lung cancer; HT, hormone therapy; HR, hazard ratio; CI, confidence interval.
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users (defined as use of 15 or more years) (relative risk, 0.22; 
95% CI, 0.04–1.15).29 Huang et al. observed that postmeno-
pausal women with lung cancer and a history of HT use had an 
increased survival time, but the difference was not statistically 
significant (p = 0.12). The authors did find significantly better 
survival among smokers who had taken HT compared with 
smokers who had not taken HT (median survival, 16.2 versus 
10.4 months; p = 0.04); however, this result was not significant 
in a multivariate analysis.20 In our study, hormone use and lon-
ger duration of use were associated with an increased survival 
of NSCLC among both smokers and never smokers in multi-
variate analysis. Conversely, another more recent study found 
that women with lung cancer taking HT were at significantly 
greater risk of death compared with women with lung cancer 
who had never taken HT (HR = 1.97; 95% CI, 1.14–3.39), and 
this relationship was even more dramatic among those with a 
smoking history.18 None of these studies reported HT duration 
or distinguish between the types of HT taken.
In our study, HT use did not predict survival among those 
who took estrogen only, except among long-term users. HT use 
was associated with better survival among women who had 
taken combined estrogen plus progesterone and this result was 
pronounced for women taking combined HT for 11 years or 
longer. Our results contrast those of the WHI’s randomized con-
trolled trial study which assessed use of estrogen alone among 
postmenopausal women who had a hysterectomy and combined 
estrogen plus progesterone in postmenopausal women with no 
previous hysterectomy.8,9 These studies concluded that although 
estrogen-only therapy did not influence lung cancer incidence or 
mortality, combined estrogen plus progesterone use increased 
the number of deaths from lung cancer. There are advantages 
to the WHI trial including the randomized double-blind design 
with standardized dosing and centralized review of lung cancer 
outcomes. The clinical trial design more effectively controls for 
potential confounding associated with factors that affect HT use 
and outcomes such as race and smoking history. There are also 
limitations to the WHI studies such as a lack of treatment data 
and limited time of HT use.
The epidemiologic literature as described remains 
inconsistent. None of the studies directly address the same 
TABLE 3.  Studies of HT and Survival after a Lung Cancer Diagnosis
Author Objective Participants Results Comments
Ettinger 
et al.29
Compare specific-cause 
mortality rates in 
women with and 
without long-term 
(≥5 yr) postmenopausal 
estrogen replacement 
therapy
232 postmenopausal estrogen 
users; 222 postmenopausal 
nonusers; follow-up averaged 
18 yr
Estrogen use associated with reduced 
risk of death from lung cancer (RR, 
0.22; 95% CI, 0.04–1.15)
Although overall mortality in this 
group was reduced most for women 
with longer duration of use, duration 
of use data was not provided for 
lung cancer mortality. Treatment 
and stage information were not 
included.
Ganti 
et al.18
Determine the impact of 
hormone replacement 
therapy on lung cancer 
survival
498 women with lung cancer 
(86 HT users); follow-up was 
presented for 10 years
Hormone use associated with increased 
risk of death from lung cancer (HR, 
1.97; 95% CI, 1.14–3.39); this effect 
was stronger in smokers; there was 
no association between HT use and 
survival in never smokers
No HT type, dose, or duration of 
use data were available; included 
women with small-cell lung cancer 
(24%).
Huang 
et al.20
Determine whether history 
of HT use (either E only 
or E + P) is associated 
with lung cancer 
survival
648 postmenopausal women (114 
HT users)
Non-significant improved survival 
among HT users (median survival, 
16.4 vs. 10.5 mo; p = 0.12); in 
analyses adjusted for age, stage, and 
smoking, there was no association 
between HT use and survival
Smoking data were missing for 25% 
of the cases; stage of diagnosis 
was available; no HT type, dose, or 
duration of use data were available.
Ayeni 
et al.19
Determine whether HT is 
associated with survival 
after a lung cancer 
diagnosis
397 women with lung cancer (115 
HT users); 6-yr follow-up
HT not associated with outcomes of 
lung cancer in women even after 
adjustment for stage, age, treatment 
type, performance status, and weight 
loss
No HT type, dose, or duration of use 
data were available.
Chlebowski 
et al.9
Compare incidence 
and mortality from 
lung cancer in 
women enrolled in a 
randomized clinical 
trial of estrogen plus 
progesterone vs. placebo
8506 postmenopausal women 
assigned to combined 
therapy (70 deaths); 8102 
postmenopausal women 
assigned to placebo (40 deaths); 
mean of 5.6 yr of treatment and 
2.4 yr of follow-up
Combined estrogen plus progesterone 
use was associated with risk of death 
from non–small-cell lung cancer
 (HR, 1.71; 95% CI, 1.16–2.52)
Randomized, controlled trial so 
that dose and duration of use are 
controlled; no association with 
lung cancer incidence; no treatment 
information for women with lung 
cancer; women in the treatment 
arm were more likely to have lung 
cancer with distant metastases.
Chlebowski 
et al.8
Compare incidence 
and mortality from 
lung cancer in 
women enrolled in a 
randomized clinical trial 
of estrogen vs. placebo
5310 postmenopausal women 
assigned to conjugated equine 
estrogen (34 deaths); 5439 
postmenopausal women 
assigned to placebo (33 deaths); 
mean follow-up of 7.9 yr
Estrogen use alone was not associated 
with risk of death from lung cancer 
(HR, 1.07; 95% CI, 0.66–1.72)
Randomized, controlled trial so 
that dose and duration of use are 
controlled; no association with 
lung cancer incidence; no treatment 
information for women with lung 
cancer.
HT, hormone therapy; RR, relative risk; CI, confidence interval.
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question because timing of use, type used, dose and duration 
of use, and unmeasured confounders vary between studies 
limiting the conclusions that can be drawn. The role of hor-
mone exposures 11 or more years before a lung cancer diag-
nosis may impact outcomes differently than shorter exposures 
closer to the time of diagnosis, or use after diagnosis. Women 
using HT may also be different from women not using HT 
in terms of unmeasured confounders such as comorbidities, 
socioeconomic status, body mass index, or differential inter-
actions with the medical system that affect outcomes.
The mechanisms underlying the association between 
estrogens and lung cancer are being evaluated in preclinical 
and clinical settings. Estrogens promote both cell proliferation 
and the transcription of estrogen-responsive genes. Estrogen 
action is through two distinct receptors, estrogen receptor 
(ER)-α and ER-β, both of which are expressed in the lung and 
localized in the cytoplasm and in the nucleus.30,31 Estrogen can 
be synthesized in the lung by aromatase, and high aromatase 
expression has been associated with poor prognosis in post-
menopausal women with early lung cancer.32 Progesterone 
action, mediated by progesterone receptor (PR), is thought to 
stimulate tissue differentiation and inhibit cell proliferation.31 
Progesterone supplementation has been shown to inhibit the 
growth of PR-positive lung tumors in mice.33 The interplay 
between estrogen and progesterone in lung carcinogenesis is 
not well understood and, in the epidemiologic literature, com-
bined HT seems to be driving findings.
Stabile et al.34 report that both cytoplasmic and nuclear 
expression of ERs and PR predict overall survival and time 
to progression. High cytoplasmic ER-β is associated with 
reduced survival, whereas low total PR is a negative predictor 
of time to progression, even after adjustment for age, stage, 
sex, and smoking. Patients with the combined expression char-
acteristics of low ER-β, low aromatase, low EGFR, and high 
PR had shorter overall survival compared with patients with 
the opposite pattern (HR, 6.6; 95% CI, 1.7–25.2). Expression 
varied by smoking status with never and former smokers hav-
ing higher expression of nuclear ER-α, cytoplasmic PR, and 
total PR. Overall survival was higher in women compared with 
men, and no survival differences were noted by menopausal 
status. In an earlier study we conducted, which included some 
of the women from this current study, we evaluated the role 
of ER-β expression in lung tumors on survival; we also had 
HT information for some of the women.35 In that study, ER-β 
expression was not associated with use of HT before diag-
nosis or with any reproductive factors, but this was a small 
study with limited follow-up. If outcomes are truly mediated 
by tumor expression of ERs and PR, the role of HT in lung 
cancer mortality may be dependent on tumor characteristics 
that have not been evaluated in the epidemiologic literature.
Strengths of our study include the use of a large 
 population-based sample, detailed information on HT type, 
duration of HT, the inclusion of a large proportion of cases 
with a history of HT use (n = 230, 47.5%), and the long-term 
follow-up of cases. Some limitations are of note. Reproductive 
and hormonal factors are based on recollection, so there is 
a potential for recall bias. We did use a calendar to trigger 
memories of important events in the woman’s life to minimize 
this bias. Overall, the study had 80% power to detect an HR 
associated with the use of HT of 0.73. Some of the stratified 
analyses included smaller numbers of women, so those results 
should be interpreted with caution. Women in the study were 
healthy enough to participate in the survey and this is reflected 
in longer overall survival than might be expected for lung can-
cer cases, so this study may not be generalizable to all women 
with NSCLC.
In conclusion, our study examines the influence of both 
reproductive and hormonal factors on NSCLC outcomes. 
Hormone use was associated with increased survival, par-
ticularly with use for 11 or more years, and especially among 
users of combined estrogen plus progesterone. With few con-
sistent results in the literature, more research examining the 
biological significance of long-term HT use on lung cancer 
outcomes is needed, with better characterization of tumors in 
terms of ER and PR expression.
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